TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback